1. Home
  2. IDYA vs CNXN Comparison

IDYA vs CNXN Comparison

Compare IDYA & CNXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • CNXN
  • Stock Information
  • Founded
  • IDYA 2015
  • CNXN 1982
  • Country
  • IDYA United States
  • CNXN United States
  • Employees
  • IDYA N/A
  • CNXN N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • CNXN Catalog/Specialty Distribution
  • Sector
  • IDYA Health Care
  • CNXN Consumer Discretionary
  • Exchange
  • IDYA Nasdaq
  • CNXN Nasdaq
  • Market Cap
  • IDYA 1.9B
  • CNXN 1.7B
  • IPO Year
  • IDYA 2019
  • CNXN 1998
  • Fundamental
  • Price
  • IDYA $21.23
  • CNXN $65.86
  • Analyst Decision
  • IDYA Strong Buy
  • CNXN
  • Analyst Count
  • IDYA 13
  • CNXN 0
  • Target Price
  • IDYA $53.42
  • CNXN N/A
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • CNXN 110.5K
  • Earning Date
  • IDYA 08-05-2025
  • CNXN 07-30-2025
  • Dividend Yield
  • IDYA N/A
  • CNXN 0.91%
  • EPS Growth
  • IDYA N/A
  • CNXN 6.26
  • EPS
  • IDYA N/A
  • CNXN 3.30
  • Revenue
  • IDYA $7,000,000.00
  • CNXN $2,871,139,000.00
  • Revenue This Year
  • IDYA $101.20
  • CNXN $9.74
  • Revenue Next Year
  • IDYA $286.70
  • CNXN $4.75
  • P/E Ratio
  • IDYA N/A
  • CNXN $20.00
  • Revenue Growth
  • IDYA N/A
  • CNXN 4.21
  • 52 Week Low
  • IDYA $13.45
  • CNXN $56.82
  • 52 Week High
  • IDYA $44.42
  • CNXN $77.19
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 62.23
  • CNXN 52.36
  • Support Level
  • IDYA $21.08
  • CNXN $65.73
  • Resistance Level
  • IDYA $22.37
  • CNXN $67.13
  • Average True Range (ATR)
  • IDYA 0.92
  • CNXN 1.17
  • MACD
  • IDYA -0.09
  • CNXN 0.18
  • Stochastic Oscillator
  • IDYA 61.72
  • CNXN 70.75

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About CNXN PC Connection Inc.

PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.

Share on Social Networks: